MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.